Recommended Immunization Schedules for Persons Aged 0 Through 18 Years UNITED STATES, 2016

Size: px
Start display at page:

Download "Recommended Immunization Schedules for Persons Aged 0 Through 18 Years UNITED STATES, 2016"

Transcription

1 Recommended Immunization Schedules for Persons Aged 0 Through 18 Years UNITED STATES, 2016 This schedule includes recommendations in effect as of January 1, Any dose not administered at the recommended age should be administered at a subsequent visit, when indicated and feasible. The use of a combination vaccine generally is preferred over separate injections of its equivalent component vaccines. Vaccination providers should consult the relevant Advisory Committee on Immunization Practices (ACIP) statement for detailed recommendations, available online at Clinically significant adverse events that follow vaccination should be reported to the Vaccine Adverse Event Reporting System (VAERS) online ( or by telephone ( ). The Recommended Immunization Schedules for Persons Aged 0 Through 18 Years are approved by the Advisory Committee on Immunization Practices ( American Academy of Pediatrics ( American Academy of Family Physicians ( American College of Obstetricians and Gynecologists ( U.S. Department of Health and Human Services Centers for Disease Control and Prevention

2 Figure 1. Recommended immunization schedule for persons aged 0 through 18 years United States, (FOR THOSE WHO FALL BEHIND OR START LATE, SEE THE CATCH-UP SCHEDULE [FIGURE 2]). These recommendations must be read with the footnotes that follow. For those who fall behind or start late, provide catch-up vaccination at the earliest opportunity as indicated by the green bars in Figure 1. To determine minimum intervals between doses, see the catch-up schedule (Figure 2). School entry and adolescent vaccine age groups are shaded. Vaccine Birth 1 mo 2 mos 4 mos 6 mos 9 mos 12 mos 15 mos 18 mos mos 2-3 yrs 4-6 yrs 7-10 yrs yrs yrs yrs Hepatitis B 1 (HepB) Rotavirus 2 (RV) RV1 (2-dose series); RV5 (3-dose series) See footnote 2 Diphtheria, tetanus, & acellular pertussis 3 (DTaP: <7 yrs) 4 th dose 5 th dose Haemophilus influenzae type b 4 (Hib) See footnote 4 3 rd or 4 th dose, See footnote 4 Pneumococcal conjugate 5 (PCV13) 4 th dose Inactivated poliovirus 6 (IPV: <18 yrs) 4 th dose Influenza 7 (IIV; LAIV) Annual vaccination (IIV only) 1 or 2 doses Annual vaccination (LAIV or IIV) 1 or 2 doses Annual vaccination (LAIV or IIV) 1 dose only Measles, mumps, rubella 8 (MMR) See footnote 8 Varicella 9 (VAR) Hepatitis A 10 (HepA) 2-dose series, See footnote 10 Meningococcal 11 (Hib-MenCY > 6 weeks; MenACWY-D >9 mos; MenACWY-CRM 2 mos) See footnote 11 Booster Tetanus, diphtheria, & acellular pertussis 12 (Tdap: >7 yrs) (Tdap) Human papillomavirus 13 (2vHPV: females only; 4vHPV, 9vHPV: males and females) (3-dose series) Meningococcal B 11 See footnote 11 Pneumococcal polysaccharide 5 (PPSV23) See footnote 5 Range of recommended ages for all children Range of recommended ages for catch-up immunization Range of recommended ages for certain high-risk groups This schedule includes recommendations in effect as of January 1, Any dose not administered at the recommended age should be administered at a subsequent visit, when indicated and feasible. The use of a combination vaccine generally is preferred over separate injections of its equivalent component vaccines. Vaccination providers should consult the relevant Advisory Committee on Immunization Practices (ACIP) statement for detailed recommendations, available online at Clinically significant adverse events that follow vaccination should be reported to the Vaccine Adverse Event Reporting System (VAERS) online ( or by telephone ( ). Suspected cases of vaccine-preventable diseases should be reported to the state or local health department. Additional information, including precautions and contraindications for vaccination, is available from CDC online ( or by telephone (800-CDC-INFO [ ]). This schedule is approved by the Advisory Committee on Immunization Practices (http// the American Academy of Pediatrics ( the American Academy of Family Physicians ( and the American College of Obstetricians and Gynecologists ( NOTE: The above recommendations must be read along with the footnotes of this schedule. Range of recommended ages for non-high-risk groups that may receive vaccine, subject to individual clinical decision making No recommendation

3 FIGURE 2. Catch-up immunization schedule for persons aged 4 months through 18 years who start late or who are more than 1 month behind United States, The figure below provides catch-up schedules and minimum intervals between doses for children whose vaccinations have been delayed. A vaccine series does not need to be restarted, regardless of the time that has elapsed between doses. Use the section appropriate for the child s age. Always use this table in conjunction with Figure 1 and the footnotes that follow. Children age 4 months through 6 years Vaccine Minimum Age for Dose 1 Minimum Interval Between Doses Dose 1 to Dose 2 Dose 2 to Dose 3 Dose 3 to Dose 4 Dose 4 to Dose 5 Hepatitis B 1 Birth 8 weeks and at least 16 weeks after first dose. Minimum age for the final dose is 2. Rotavirus 2 6 weeks 2 Diphtheria, tetanus, and acellular pertussis 3 6 weeks 6 months 6 months 3 4 if current age is younger than 12 months and first dose was administered at younger than age 7 months, and at least 1 previous dose was PRP-T (ActHib, Pentacel) or unknown. Haemophilus influenzae type b 4 6 weeks if first dose was administered before the 1 st birthday. 8 weeks (as final dose) if first dose was administered at age 12 through 14 months. No further doses needed if first dose was administered at age 15 months or older. 8 weeks and age 12 through 59 months (as final dose for healthy children) 4 if current age is younger than 12 months and first dose was administered at age 7 through 11 months (wait until at least 12 months old); OR if current age is 12 through 59 months and first dose was administered before the 1 st birthday, and second dose administered at younger than 15 months; OR if both doses were PRP-OMP (PedvaxHIB; Comvax) and were administered before the 1 st birthday (wait until at least 12 months old). No further doses needed if previous dose was administered at age 15 months or older. 8 weeks (as final dose) This dose only necessary for children age 12 through 59 months who received 3 doses before the 1 st birthday. Pneumococcal 5 6 weeks if first dose administered before the 1 st birthday. 8 weeks (as final dose for healthy children) if first dose was administered at the 1 st birthday or after. No further doses needed for healthy children if first dose administered at age 24 months or older. if current age is younger than 12 months and previous dose given at <7months old. 8 weeks (as final dose for healthy children) if previous dose given between 7-11 months (wait until at least 12 months old); OR if current age is 12 months or older and at least 1 dose was given before age 12 months. No further doses needed for healthy children if previous dose administered at age 24 months or older. 8 weeks (as final dose) This dose only necessary for children aged 12 through 59 months who received 3 doses before age 12 months or for children at high risk who received 3 doses at any age. Inactivated poliovirus 6 6 weeks months 6 (minimum age 4 years for final dose). Measles, mumps, rubella 8 12 months Varicella 9 12 months 3 months Hepatitis A months 6 months Meningococcal 11 (Hib-MenCY 6 weeks; MenACWY-D 9 mos; MenACWY-CRM 2 mos) 6 weeks 8 weeks 11 See footnote 11 See footnote 11 Children and adolescents age 7 through 18 years Meningococcal 11 (Hib-MenCY 6 weeks; MenACWY-D 9 mos; MenACWY-CRM 2 mos) Not Applicable (N/A) 8 weeks 11 Tetanus, diphtheria; tetanus, diphtheria, and 7 years 12 acellular pertussis 12 if first dose of DTaP/DT was administered before the 1 st birthday. 6 months (as final dose) if first dose of DTaP/DT or Tdap/Td was administered at or after the 1 st birthday. 6 months if first dose of DTaP/DT was administered before the 1 st birthday. Human papillomavirus 13 9 years Routine dosing intervals are recommended. 13 Hepatitis A 10 N/A 6 months Hepatitis B 1 N/A 8 weeks and at least 16 weeks after first dose. Inactivated poliovirus 6 N/A 6 6 months 6 Meningococcal 11 N/A 8 weeks 11 Measles, mumps, rubella 8 N/A Varicella 9 N/A 3 months if younger than age 13 years. if age 13 years or older. NOTE: The above recommendations must be read along with the footnotes of this schedule.

4 Footnotes Recommended immunization schedule for persons aged 0 through 18 years United States, 2016 For further guidance on the use of the vaccines mentioned below, see: For vaccine recommendations for persons 19 years of age and older, see the Adult Immunization Schedule. Additional information For contraindications and precautions to use of a vaccine and for additional information regarding that vaccine, vaccination providers should consult the relevant ACIP statement available online at For purposes of calculating intervals between doses, = 28 days. Intervals of 4 months or greater are determined by calendar months. Vaccine doses administered 4 days or less before the minimum interval are considered valid. Doses of any vaccine administered 5 days earlier than the minimum interval or minimum age should not be counted as valid doses and should be repeated as age-appropriate. The repeat dose should be spaced after the invalid dose by the recommended minimum interval. For further details, see MMWR, General Recommendations on Immunization and Reports / Vol. 60 / No. 2; Table 1. Recommended and minimum ages and intervals between vaccine doses available online at Information on travel vaccine requirements and recommendations is available at For vaccination of persons with primary and secondary immunodeficiencies, see Table 13, Vaccination of persons with primary and secondary immunodeficiencies, in General Recommendations on Immunization (ACIP), available at and American Academy of Pediatrics. Immunization in Special Clinical Circumstances, in Kimberlin DW, Brady MT, Jackson MA, Long SS eds. Red Book: 2015 report of the Committee on Infectious Diseases. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics. 1. Hepatitis B (HepB) vaccine. (Minimum age: birth) At birth: Administer monovalent HepB vaccine to all newborns before hospital discharge. For infants born to hepatitis B surface antigen (HBsAg)-positive mothers, administer HepB vaccine and 0.5 ml of hepatitis B immune globulin (HBIG) within 12 hours of birth. These infants should be tested for HBsAg and antibody to HBsAg (anti-hbs) at age 9 through 18 months (preferably at the next wellchild visit) or 1 to 2 months after completion of the HepB series if the series was delayed; CDC recently recommended testing occur at age 9 through 12 months; see mmwrhtml/mm6439a6.htm. If mother s HBsAg status is unknown, within 12 hours of birth administer HepB vaccine regardless of birth weight. For infants weighing less than 2,000 grams, administer HBIG in addition to HepB vaccine within 12 hours of birth. Determine mother s HBsAg status as soon as possible and, if mother is HBsAg-positive, also administer HBIG for infants weighing 2,000 grams or more as soon as possible, but no later than age 7 days. Doses following the birth dose: The second dose should be administered at age 1 or 2 months. Monovalent HepB vaccine should be used for doses administered before age 6 weeks. Infants who did not receive a birth dose should receive 3 doses of a HepB-containing vaccine on a schedule of 0, 1 to 2 months, and 6 months starting as soon as feasible. See Figure 2. Administer the second dose 1 to 2 months after the first dose (minimum interval of ), administer the third dose at least 8 weeks after the second dose AND at least 16 weeks after the first dose. The final (third or fourth) dose in the HepB vaccine series should be administered no earlier than age 2. Administration of a total of 4 doses of HepB vaccine is permitted when a combination vaccine containing HepB is administered after the birth dose. Unvaccinated persons should complete a 3-dose series. A 2-dose series (doses separated by at least 4 months) of adult formulation Recombivax HB is licensed for use in children aged 11 through 15 years. 2. Rotavirus (RV) vaccines. (Minimum age: 6 weeks for both RV1 [Rotarix] and RV5 [RotaTeq]) Administer a series of RV vaccine to all infants as follows: 1. If Rotarix is used, administer a 2-dose series at 2 and 4 months of age. 2. If RotaTeq is used, administer a 3-dose series at ages 2, 4, and 6 months. 3. If any dose in the series was RotaTeq or vaccine product is unknown for any dose in the series, a total of 3 doses of RV vaccine should be administered. The maximum age for the first dose in the series is 1, 6 days; vaccination should not be initiated for infants aged 15 weeks, 0 days or older. The maximum age for the final dose in the series is 8 months, 0 days. 3. Diphtheria and tetanus toxoids and acellular pertussis (DTaP) vaccine. (Minimum age: 6 weeks. Exception: DTaP-IPV [Kinrix, Quadracel]: 4 years) Administer a 5-dose series of DTaP vaccine at ages 2, 4, 6, 15 through 18 months, and 4 through 6 years. The fourth dose may be administered as early as age 12 months, provided at least 6 months have elapsed since the third dose. Inadvertent administration of 4th DTaP dose early: If the fourth dose of DTaP was administered at least 4 months, but less than 6 months, after the third dose of DTaP, it need not be repeated. 3. Diphtheria and tetanus toxoids and acellular pertussis (DTaP) vaccine (cont d) The fifth dose of DTaP vaccine is not necessary if the fourth dose was administered at age 4 years or older. 4. Haemophilus influenzae type b (Hib) conjugate vaccine. (Minimum age: 6 weeks for PRP-T [AC- THIB, DTaP-IPV/Hib (Pentacel) and Hib-MenCY (MenHibrix)], PRP-OMP [PedvaxHIB or COMVAX], 12 months for PRP-T [Hiberix]) Administer a 2- or 3-dose Hib vaccine primary series and a booster dose (dose 3 or 4 depending on vaccine used in primary series) at age 12 through 15 months to complete a full Hib vaccine series. The primary series with ActHIB, MenHibrix, or Pentacel consists of 3 doses and should be administered at 2, 4, and 6 months of age. The primary series with PedvaxHib or COMVAX consists of 2 doses and should be administered at 2 and 4 months of age; a dose at age 6 months is not indicated. One booster dose (dose 3 or 4 depending on vaccine used in primary series) of any Hib vaccine should be administered at age 12 through 15 months. An exception is Hiberix vaccine. Hiberix should only be used for the booster (final) dose in children aged 12 months through 4 years who have received at least 1 prior dose of Hib-containing vaccine. For recommendations on the use of MenHibrix in patients at increased risk for meningococcal disease, please refer to the meningococcal vaccine footnotes and also to MMWR February 28, 2014 / 63(RR01);1-13, available at If dose 1 was administered at ages 12 through 14 months, administer a second (final) dose at least 8 weeks after dose 1, regardless of Hib vaccine used in the primary series. If both doses were PRP-OMP (PedvaxHIB or COMVAX), and were administered before the first birthday, the third (and final) dose should be administered at age 12 through 59 months and at least 8 weeks after the second dose. If the first dose was administered at age 7 through 11 months, administer the second dose at least later and a third (and final) dose at age 12 through 15 months or 8 weeks after second dose, whichever is later. If first dose is administered before the first birthday and second dose administered at younger than 15 months, a third (and final) dose should be administered 8 weeks later. For unvaccinated children aged 15 months or older, administer only 1 dose. For catch-up guidance related to MenHibrix, please see the meningococcal vaccine footnotes and also MMWR February 28, 2014 / 63(RR01);1-13, available at Vaccination of persons with high-risk conditions: Children aged 12 through 59 months who are at increased risk for Hib disease, including chemotherapy recipients and those with anatomic or functional asplenia (including sickle cell disease), human immunodeficiency virus (HIV ) infection, immunoglobulin deficiency, or early component complement deficiency, who have received either no doses or only 1 dose of Hib vaccine before 12 months of age, should receive 2 additional doses of Hib vaccine 8 weeks apart; children who received 2 or more doses of Hib vaccine before 12 months of age should receive 1 additional dose. For patients younger than 5 years of age undergoing chemotherapy or radiation treatment who received a Hib vaccine dose(s) within 14 days of starting therapy or during therapy, repeat the dose(s) at least 3 months following therapy completion. Recipients of hematopoietic stem cell transplant (HSCT) should be revaccinated with a 3-dose regimen of Hib vaccine starting 6 to 12 months after successful transplant, regardless of vaccination history; doses should be administered at least apart. A single dose of any Hib-containing vaccine should be administered to unimmunized* children and adolescents 15 months of age and older undergoing an elective splenectomy; if possible, vaccine should be administered at least 14 days before procedure.

5 For further guidance on the use of the vaccines mentioned below, see: 4. Haemophilus influenzae type b (Hib) conjugate vaccine (cont d) Hib vaccine is not routinely recommended for patients 5 years or older. However, 1 dose of Hib vaccine should be administered to unimmunized* persons aged 5 years or older who have anatomic or functional asplenia (including sickle cell disease) and unvaccinated persons 5 through 18 years of age with HIV infection. * Patients who have not received a primary series and booster dose or at least 1 dose of Hib vaccine after 14 months of age are considered unimmunized. 5. Pneumococcal vaccines. (Minimum age: 6 weeks for PCV13, 2 years for PPSV23) Routine vaccination with PCV13: Administer a 4-dose series of PCV13 vaccine at ages 2, 4, and 6 months and at age 12 through 15 months. For children aged 14 through 59 months who have received an age-appropriate series of 7-valent PCV (PCV7), administer a single supplemental dose of 13-valent PCV (PCV13). Catch-up vaccination with PCV13: Administer 1 dose of PCV13 to all healthy children aged 24 through 59 months who are not completely vaccinated for their age. Vaccination of persons with high-risk conditions with PCV13 and PPSV23: All recommended PCV13 doses should be administered prior to PPSV23 vaccination if possible. For children 2 through 5 years of age with any of the following conditions: chronic heart disease (particularly cyanotic congenital heart disease and cardiac failure); chronic lung disease (including asthma if treated with high-dose oral corticosteroid therapy); diabetes mellitus; cerebrospinal fluid leak; cochlear implant; sickle cell disease and other hemoglobinopathies; anatomic or functional asplenia; HIV infection; chronic renal failure; nephrotic syndrome; diseases associated with treatment with immunosuppressive drugs or radiation therapy, including malignant neoplasms, leukemias, lymphomas, and Hodgkin disease; solid organ transplantation; or congenital immunodeficiency: 1. Administer 1 dose of PCV13 if any incomplete schedule of 3 doses of PCV (PCV7 and/or PCV13) were received previously. 2. Administer 2 doses of PCV13 at least 8 weeks apart if unvaccinated or any incomplete schedule of fewer than 3 doses of PCV (PCV7 and/or PCV13) were received previously. 3. Administer 1 supplemental dose of PCV13 if 4 doses of PCV7 or other age-appropriate complete PCV7 series was received previously. 4. The minimum interval between doses of PCV (PCV7 or PCV13) is 8 weeks. 5. For children with no history of PPSV23 vaccination, administer PPSV23 at least 8 weeks after the most recent dose of PCV13. For children aged 6 through 18 years who have cerebrospinal fluid leak; cochlear implant; sickle cell disease and other hemoglobinopathies; anatomic or functional asplenia; congenital or acquired immunodeficiencies; HIV infection; chronic renal failure; nephrotic syndrome; diseases associated with treatment with immunosuppressive drugs or radiation therapy, including malignant neoplasms, leukemias, lymphomas, and Hodgkin disease; generalized malignancy; solid organ transplantation; or multiple myeloma: 1. If neither PCV13 nor PPSV23 has been received previously, administer 1 dose of PCV13 now and 1 dose of PPSV23 at least 8 weeks later. 2. If PCV13 has been received previously but PPSV23 has not, administer 1 dose of PPSV23 at least 8 weeks after the most recent dose of PCV If PPSV23 has been received but PCV13 has not, administer 1 dose of PCV13 at least 8 weeks after the most recent dose of PPSV23. For children aged 6 through 18 years with chronic heart disease (particularly cyanotic congenital heart disease and cardiac failure), chronic lung disease (including asthma if treated with high-dose oral corticosteroid therapy), diabetes mellitus, alcoholism, or chronic liver disease, who have not received PPSV23, administer 1 dose of PPSV23. If PCV13 has been received previously, then PPSV23 should be administered at least 8 weeks after any prior PCV13 dose. A single revaccination with PPSV23 should be administered 5 years after the first dose to children with sickle cell disease or other hemoglobinopathies; anatomic or functional asplenia; congenital or acquired immunodeficiencies; HIV infection; chronic renal failure; nephrotic syndrome; diseases associated with treatment with immunosuppressive drugs or radiation therapy, including malignant neoplasms, leukemias, lymphomas, and Hodgkin disease; generalized malignancy; solid organ transplantation; or multiple myeloma. 6. Inactivated poliovirus vaccine (IPV). (Minimum age: 6 weeks) Administer a 4-dose series of IPV at ages 2, 4, 6 through 18 months, and 4 through 6 years. The final dose in the series should be administered on or after the fourth birthday and at least 6 months after the previous dose. In the first 6 months of life, minimum age and minimum intervals are only recommended if the person is at risk of imminent exposure to circulating poliovirus (i.e., travel to a polio-endemic region or during an outbreak). If 4 or more doses are administered before age 4 years, an additional dose should be administered at age 4 through 6 years and at least 6 months after the previous dose. A fourth dose is not necessary if the third dose was administered at age 4 years or older and at least 6 months after the previous dose. 6. Inactivated poliovirus vaccine (IPV). (Minimum age: 6 weeks) (cont d) If both OPV and IPV were administered as part of a series, a total of 4 doses should be administered, regardless of the child s current age. If only OPV were administered, and all doses were given prior to 4 years of age, one dose of IPV should be given at 4 years or older, at least after the last OPV dose. IPV is not routinely recommended for U.S. residents aged 18 years or older. 7. Influenza vaccines. (Minimum age: 6 months for inactivated influenza vaccine [IIV], 2 years for live, attenuated influenza vaccine [LAIV]) Administer influenza vaccine annually to all children beginning at age 6 months. For most healthy, nonpregnant persons aged 2 through 49 years, either LAIV or IIV may be used. However, LAIV should NOT be administered to some persons, including 1) persons who have experienced severe allergic reactions to LAIV, any of its components, or to a previous dose of any other influenza vaccine; 2) children 2 through 17 years receiving aspirin or aspirin-containing products; 3) persons who are allergic to eggs; 4) pregnant women; 5) immunosuppressed persons; 6) children 2 through 4 years of age with asthma or who had wheezing in the past 12 months; or 7) persons who have taken influenza antiviral medications in the previous 48 hours. For all other contraindications and precautions to use of LAIV, see MMWR August 7, 2015 / 64(30): available at For children aged 6 months through 8 years: For the season, administer 2 doses (separated by at least ) to children who are receiving influenza vaccine for the first time. Some children in this age group who have been vaccinated previously will also need 2 doses. For additional guidance, follow dosing guidelines in the ACIP influenza vaccine recommendations, MMWR August 7, 2015 / 64(30):818-25, available at mmwr/pdf/wk/mm6430.pdf. For the season, follow dosing guidelines in the 2016 ACIP influenza vaccine recommendations. For persons aged 9 years and older: Administer 1 dose. 8. Measles, mumps, and rubella (MMR) vaccine. (Minimum age: 12 months for routine vaccination) Administer a 2-dose series of MMR vaccine at ages 12 through 15 months and 4 through 6 years. The second dose may be administered before age 4 years, provided at least have elapsed since the first dose. Administer 1 dose of MMR vaccine to infants aged 6 through 11 months before departure from the United States for international travel. These children should be revaccinated with 2 doses of MMR vaccine, the first at age 12 through 15 months (12 months if the child remains in an area where disease risk is high), and the second dose at least later. Administer 2 doses of MMR vaccine to children aged 12 months and older before departure from the United States for international travel. The first dose should be administered on or after age 12 months and the second dose at least later. Ensure that all school-aged children and adolescents have had 2 doses of MMR vaccine; the minimum interval between the 2 doses is. 9. Varicella (VAR) vaccine. (Minimum age: 12 months) Administer a 2-dose series of VAR vaccine at ages 12 through 15 months and 4 through 6 years. The second dose may be administered before age 4 years, provided at least 3 months have elapsed since the first dose. If the second dose was administered at least after the first dose, it can be accepted as valid. Ensure that all persons aged 7 through 18 years without evidence of immunity (see MMWR 2007 / 56 [No. RR-4], available at ) have 2 doses of varicella vaccine. For children aged 7 through 12 years, the recommended minimum interval between doses is 3 months (if the second dose was administered at least after the first dose, it can be accepted as valid); for persons aged 13 years and older, the minimum interval between doses is. 10. Hepatitis A (HepA) vaccine. (Minimum age: 12 months) Initiate the 2-dose HepA vaccine series at 12 through 23 months; separate the 2 doses by 6 to 18 months. Children who have received 1 dose of HepA vaccine before age 24 months should receive a second dose 6 to 18 months after the first dose. For any person aged 2 years and older who has not already received the HepA vaccine series, 2 doses of HepA vaccine separated by 6 to 18 months may be administered if immunity against hepatitis A virus infection is desired. The minimum interval between the 2 doses is 6 months.

6 For further guidance on the use of the vaccines mentioned below, see: Hepatitis A (HepA) vaccine (cont d) Special populations: Administer 2 doses of HepA vaccine at least 6 months apart to previously unvaccinated persons who live in areas where vaccination programs target older children, or who are at increased risk for infection. This includes persons traveling to or working in countries that have high or intermediate endemicity of infection; men having sex with men; users of injection and non-injection illicit drugs; persons who work with HAV-infected primates or with HAV in a research laboratory; persons with clotting-factor disorders; persons with chronic liver disease; and persons who anticipate close personal contact (e.g., household or regular babysitting) with an international adoptee during the first 60 days after arrival in the United States from a country with high or intermediate endemicity. The first dose should be administered as soon as the adoption is planned, ideally 2 or more weeks before the arrival of the adoptee. 11. Meningococcal vaccines. (Minimum age: 6 weeks for Hib-MenCY [MenHibrix], 9 months for MenACWY-D [Menactra], 2 months for MenACWY-CRM [Menveo], 10 years for serogroup B meningococcal [MenB] vaccines: MenB-4C [Bexsero] and MenB-FHbp [Trumenba]) Administer a single dose of Menactra or Menveo vaccine at age 11 through 12 years, with a booster dose at age 16 years. Adolescents aged 11 through 18 years with human immunodeficiency virus (HIV ) infection should receive a 2-dose primary series of Menactra or Menveo with at least 8 weeks between doses. For children aged 2 months through 18 years with high-risk conditions, see below. Administer Menactra or Menveo vaccine at age 13 through 18 years if not previously vaccinated. If the first dose is administered at age 13 through 15 years, a booster dose should be administered at age 16 through 18 years with a minimum interval of at least 8 weeks between doses. If the first dose is administered at age 16 years or older, a booster dose is not needed. Clinical discretion: Young adults aged 16 through 23 years (preferred age range is 16 through 18 years) may be vaccinated with either a 2-dose series of Bexsero or a 3-dose series of Trumenba vaccine to provide short-term protection against most strains of serogroup B meningococcal disease. The two MenB vaccines are not interchangeable; the same vaccine product must be used for all doses. Vaccination of persons with high-risk conditions and other persons at increased risk of disease: Children with anatomic or functional asplenia (including sickle cell disease): Meningococcal conjugate ACWY vaccines: 1. Menveo o Children who initiate vaccination at 8 weeks: Administer doses at 2, 4, 6, and 12 months of age. o Unvaccinated children who initiate vaccination at 7 through 23 months: Administer 2 doses, with the second dose at least 12 weeks after the first dose AND after the first birthday. o Children 24 months and older who have not received a complete series: Administer 2 primary doses at least 8 weeks apart. 2. MenHibrix o Children who initiate vaccination at 6 weeks: Administer doses at 2, 4, 6, and 12 through 15 months of age. o If the first dose of MenHibrix is given at or after 12 months of age, a total of 2 doses should be given at least 8 weeks apart to ensure protection against serogroups C and Y meningococcal disease. 3. Menactra o Children 24 months and older who have not received a complete series: Administer 2 primary doses at least 8 weeks apart. If Menactra is administered to a child with asplenia (including sickle cell disease), do not administer Menactra until 2 years of age and at least after the completion of all PCV13 doses. Meningococcal B vaccines: 1. Bexsero or Trumenba o Persons 10 years or older who have not received a complete series. Administer a 2-dose series of Bexsero, at least 1 month apart. Or a 3-dose series of Trumenba, with the second dose at least 2 months after the first and the third dose at least 6 months after the first. The two MenB vaccines are not interchangeable; the same vaccine product must be used for all doses. Children with persistent complement component deficiency (includes persons with inherited or chronic deficiencies in C3, C5-9, properidin, factor D, factor H, or taking eculizumab (Soliriis ): Meningococcal conjugate ACWY vaccines: 1. Menveo o Children who initiate vaccination at 8 weeks: Administer doses at 2, 4, 6, and 12 months of age. o Unvaccinated children who initiate vaccination at 7 through 23 months: Administer 2 doses, with the second dose at least 12 weeks after the first dose AND after the first birthday. o Children 24 months and older who have not received a complete series: Administer 2 primary doses at least 8 weeks apart. 2. MenHibrix o Children who initiate vaccination 6 weeks: Administer doses at 2, 4, 6, and 12 through 15 months of age. o If the first dose of MenHibrix is given at or after 12 months of age, a total of 2 doses should be given at least 8 weeks apart to ensure protection against serogroups C and Y meningococcal disease. 11. Meningococcal vaccines (cont d) 3. Menactra o Children 9 through 23 months: Administer 2 primary doses at least 12 weeks apart. o Children 24 months and older who have not received a complete series: Administer 2 primary doses at least 8 weeks apart. Meningococcal B vaccines: 1. Bexsero or Trumenba o Persons 10 years or older who have not received a complete series. Administer a 2-dose series of Bexsero, at least 1 month apart. Or a 3-dose series of Trumenba, with the second dose at least 2 months after the first and the third dose at least 6 months after the first. The two MenB vaccines are not interchangeable; the same vaccine product must be used for all doses. For children who travel to or reside in countries in which meningococcal disease is hyperendemic or epidemic, including countries in the African meningitis belt or the Hajj administer an age-appropriate formulation and series of Menactra or Menveo for protection against serogroups A and W meningococcal disease. Prior receipt of MenHibrix is not sufficient for children traveling to the meningitis belt or the Hajj because it does not contain serogroups A or W. For children at risk during a community outbreak attributable to a vaccine serogroup administer or complete an age- and formulation-appropriate series of MenHibrix, Menactra, or Menveo, Bexsero or Trumenba. For booster doses among persons with high-risk conditions, refer to MMWR 2013 / 62(RR02);1-22, available at For other catch-up recommendations for these persons, and complete information on use of meningococcal vaccines, including guidance related to vaccination of persons at increased risk of infection, see MMWR March 22, 2013 / 62(RR02);1-22, and MMWR October 23, 2015 / 64(41); available at and Tetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccine. (Minimum age: 10 years for both Boostrix and Adacel) Administer 1 dose of Tdap vaccine to all adolescents aged 11 through 12 years. Tdap may be administered regardless of the interval since the last tetanus and diphtheria toxoidcontaining vaccine. Administer 1 dose of Tdap vaccine to pregnant adolescents during each pregnancy (preferred during 27 through 36 weeks gestation) regardless of time since prior Td or Tdap vaccination. Persons aged 7 years and older who are not fully immunized with DTaP vaccine should receive Tdap vaccine as 1 (preferably the first) dose in the catch-up series; if additional doses are needed, use Td vaccine. For children 7 through 10 years who receive a dose of Tdap as part of the catch-up series, an adolescent Tdap vaccine dose at age 11 through 12 years should NOT be administered. Td should be administered instead 10 years after the Tdap dose. Persons aged 11 through 18 years who have not received Tdap vaccine should receive a dose followed by tetanus and diphtheria toxoids (Td) booster doses every 10 years thereafter. Inadvertent doses of DTaP vaccine: - If administered inadvertently to a child aged 7 through 10 years may count as part of the catch-up series. This dose may count as the adolescent Tdap dose, or the child can later receive a Tdap booster dose at age 11 through 12 years. - If administered inadvertently to an adolescent aged 11 through 18 years, the dose should be counted as the adolescent Tdap booster. 13. Human papillomavirus (HPV) vaccines. (Minimum age: 9 years for 2vHPV [Cervarix], 4vHPV [Gardasil] and 9vHPV [Gardasil 9]) Administer a 3-dose series of HPV vaccine on a schedule of 0, 1-2, and 6 months to all adolescents aged 11 through 12 years. 9vHPV, 4vHPV or 2vHPV may be used for females, and only 9vHPV or 4vHPV may be used for males. The vaccine series may be started at age 9 years. Administer the second dose 1 to 2 months after the first dose (minimum interval of ); administer the third dose 16 weeks after the second dose (minimum interval of 12 weeks) and 2 after the first dose. Administer HPV vaccine beginning at age 9 years to children and youth with any history of sexual abuse or assault who have not initiated or completed the 3-dose series. Administer the vaccine series to females (2vHPV or 4vHPV or 9vHPV) and males (4vHPV or 9vHPV) at age 13 through 18 years if not previously vaccinated. Use recommended routine dosing intervals (see Routine vaccination above) for vaccine series catch-up. CS A

NOTE: The above recommendations must be read along with the footnotes of this schedule.

NOTE: The above recommendations must be read along with the footnotes of this schedule. Figure 1. Recommended immunization schedule for persons aged 0 through 18 years United States, 2014. (FOR THOSE WHO FALL BEHIND OR START LATE, SEE THE CATCH-UP SCHEDULE [FIGURE 2]). These recommendations

More information

3 rd dose. 3 rd or 4 th dose, see footnote 5. see footnote 13. for certain high-risk groups

3 rd dose. 3 rd or 4 th dose, see footnote 5. see footnote 13. for certain high-risk groups Figure 1. Recommended immunization schedule for persons aged 0 through 18 years 2013. (FOR THOSE WHO FALL BEHIND OR START LATE, SEE THE CATCH-UP SCHEDULE [FIGURE 2]). These recommendations must be read

More information

NOTE: The above recommendations must be read along with the footnotes of this schedule.

NOTE: The above recommendations must be read along with the footnotes of this schedule. Figure 1. Recommended immunization schedule for persons aged 0 through 18 years 2013. (FOR THOSE WHO FALL BEHIND OR START LATE, SEE THE CATCH-UP SCHEDULE [FIGURE 2]). These recommendations must be read

More information

Recommendations for Preventive Pediatric Health Care

Recommendations for Preventive Pediatric Health Care Recommendations for Preventive Pediatric Health Care Bright Futures/American Academy of Pediatrics Each child and family is unique; therefore, these Recommendations for Preventive Pediatric Health Care

More information

12 mos. 15 mos. 4 th dose. 3 rd or 4th dose, see footnote 5. dose. 4 th. dose. dose. See footnote 13

12 mos. 15 mos. 4 th dose. 3 rd or 4th dose, see footnote 5. dose. 4 th. dose. dose. See footnote 13 Figure 1. Recommended Immunization Schedule for Persons Aged 0 through 18 Years - 2013 (FOR THOSE WHO FALL BEHIND OR START LATE, SEE THE CATCH-UP SCHEDULE [FIGURE 2]) These recommendations must be read

More information

Immunization Resources for Pharmacists

Immunization Resources for Pharmacists Immunization Resources for Pharmacists TABLE OF CONTENTS Child / Teen Resources Screening Questionnaire Child/Teen... 3 Vaccine Schedule Age 0-6yrs... 5 Catch-Up Schedule 4mo-18yrs... 6 Vaccine Schedule

More information

POLICIES AND PROCEDURES

POLICIES AND PROCEDURES Purpose: To establish guidelines for Childhood Preventive Care Screening.To specify and define the Alliance guidelines for periodic health screening and preventive health services for members up to 21

More information

What DO the childhood immunization footnotes reveal? Questions and answers

What DO the childhood immunization footnotes reveal? Questions and answers What DO the childhood immunization footnotes reveal? Questions and answers Stanley E. Grogg, DO, FACOP, FAAP he Advisory Committee on Immunization Practices (ACIP) recommends the childhood vaccination

More information

Immunization Nation: Update on Pediatric Vaccines. Objectives

Immunization Nation: Update on Pediatric Vaccines. Objectives Immunization Nation: Update on Pediatric Vaccines Leigh Peek, PharmD, BCPS Pediatric Clinical Pharmacy Specialist The Children s Hospital at OU Medical System Objectives 1. Address current controversies

More information

Immunization Guidelines for the Use of State Supplied Vaccine May 17, 2015

Immunization Guidelines for the Use of State Supplied Vaccine May 17, 2015 DTaP / DT DTaP/IPV/Hep B Combination (Pediarix ) Children from 6 weeks of age up to the 7 th birthday Children from 2 months of age up to the 7th birthday: Indicated for the primary doses of DTaP, IPV,

More information

Immunization Guidelines for the Use of State Supplied Vaccine April 18, 2013

Immunization Guidelines for the Use of State Supplied Vaccine April 18, 2013 DTaP / DT DTaP/IPV/Hep B Combination (Pediarix ) Children from 6 weeks of age up to the 7 th birthday Children from 2 months of age up to the 7th birthday: Indicated for the primary doses of DTaP, IPV,

More information

Note from the National Guideline Clearinghouse (NGC): The guideline recommendations are presented in the form of tables with footnotes (see below).

Note from the National Guideline Clearinghouse (NGC): The guideline recommendations are presented in the form of tables with footnotes (see below). Brief Summary GUIDELINE TITLE Recommended immunization schedules for persons aged 0 through 18 years: United States, 2009. BIBLIOGRAPHIC SOURCE(S) American Academy of Pediatrics Committee on Infectious

More information

Immunization Guidelines For the Use of State Supplied Vaccine July 1, 2011

Immunization Guidelines For the Use of State Supplied Vaccine July 1, 2011 DTaP / DT DTaP/IPV/Hep B Combination (Pediarix ) Children from 6 weeks of age up to the 7 th birthday Children from 2 months of age up to the 7th birthday: Indicated for the primary doses of DTaP, IPV,

More information

New Jersey Department of Health Vaccine Preventable Disease Program Childhood and Adolescent Recommended Vaccines

New Jersey Department of Health Vaccine Preventable Disease Program Childhood and Adolescent Recommended Vaccines New Jersey Department of Health Vaccine Preventable Disease Program Childhood and Adolescent Recommended Vaccines Antigens Vaccine Approved Age Daptacel Diphtheria, Tetanus, and acellular Pertussis (DTaP)

More information

Recommended Immunization Schedule for Adults Aged 19 Years or Older, United States, 2017

Recommended Immunization Schedule for Adults Aged 19 Years or Older, United States, 2017 Recommended Immunization Schedule for Adults Aged 19 Years or Older, United States, 2017 In February 2017, the Recommended Immunization Schedule for Adults Aged 19 Years or Older, United States, 2017 became

More information

Quality Reporting. and Performance Measures GAPEC

Quality Reporting. and Performance Measures GAPEC Quality Reporting and Performance Measures GAPEC-1706-16 https://providers.amerigroup.com Table of contents Performance measures Introduction... 3 Quality reporting and performance measures... 4 Resources

More information

Massachusetts Department of Public Health Recommended Immunization Schedule for Persons Aged 0-6 Years, 2007

Massachusetts Department of Public Health Recommended Immunization Schedule for Persons Aged 0-6 Years, 2007 Vaccine Hepatitis B 1 Birth HepB 1 month Rotavirus 2 Rota Rota Rota Diphtheria, Tetanus, Pertussis 3 DTaP DTaP DTaP Haemophilus influenzae type b 4 Hib Hib Hib 4 Pneumococcal 5 PCV PCV PCV Inactivated

More information

RECOMMENDED IMMUNIZATIONS

RECOMMENDED IMMUNIZATIONS Recommended Immunization Schedule for Persons Aged 0 Through 6 Years United States 2010 1 2 4 6 12 15 18 19 23 2 3 4 6 Vaccine Age Birth month months months months months months months months years years

More information

TRICARE Retail Vaccination Program Vaccine List - September 2018*

TRICARE Retail Vaccination Program Vaccine List - September 2018* Diphtheria, tetanus and pertussis Diphtheria and tetanus toxoids adsorbed acellular pertussis adsorbed DT DTaP Diphtheria and tetanus toxoids adsorbed Daptacel, Infanrix Tetanus and diphtheria toxoids

More information

PREVENTIVE IMMUNIZATIONS. PREVENTIVE IMMUNIZATIONS These codes do not have a diagnosis code requirement for preventive benefits to apply.

PREVENTIVE IMMUNIZATIONS. PREVENTIVE IMMUNIZATIONS These codes do not have a diagnosis code requirement for preventive benefits to apply. An immunization that does not fall under one of the exclusions in the Certificate of Coverage is considered covered after the following conditions are satisfied: (1) FDA approval; (2) explicit ACIP recommendation

More information

PREVENTIVE IMMUNIZATIONS. PREVENTIVE IMMUNIZATIONS These codes do not have a diagnosis code requirement for preventive benefits to apply.

PREVENTIVE IMMUNIZATIONS. PREVENTIVE IMMUNIZATIONS These codes do not have a diagnosis code requirement for preventive benefits to apply. An immunization that does not fall under one of the exclusions in the Certificate of Coverage is considered covered after the following conditions are satisfied: (1) FDA approval; (2) explicit ACIP recommendation

More information

GENERAL IMMUNIZATION GUIDE FOR CHILDCARE PROVIDERS August 2018 **CHILD VACCINES** DIPHTHERIA, TETANUS, PERTUSSIS VACCINES

GENERAL IMMUNIZATION GUIDE FOR CHILDCARE PROVIDERS August 2018 **CHILD VACCINES** DIPHTHERIA, TETANUS, PERTUSSIS VACCINES GENERAL IMMUNIZATION GUIDE FOR CHILDCARE PROVIDERS August 2018 **CHILD VACCINES** DIPHTHERIA, TETANUS, PERTUSSIS VACCINES DTaP: Diphtheria, Tetanus, acellular Pertussis Vaccine Infanrix Licensed in 1997

More information

Series of 2 doses, 6-12 months apart. One dose is 720 Elu/0.5ml (GSK) or 25 u/0.5 ml (Merck)

Series of 2 doses, 6-12 months apart. One dose is 720 Elu/0.5ml (GSK) or 25 u/0.5 ml (Merck) UTAH PREVENTIVE CARE RECOMMENDATIONS Adult - Ages 19 and Above IMMUNIZATIONS CONTENTS: General Instructions Hepatitis A Hepatitis B Human Papilloma Virus Influenza Meningococcal A, C, Y, W (MCV4) Meningococcal

More information

Lessons Three and Four Safety, Health, and Care parts 1 and 2 (2 class periods)

Lessons Three and Four Safety, Health, and Care parts 1 and 2 (2 class periods) Parenting: A High School Guide to Parenting Skills for Life Lessons Three and Four Safety, Health, and Care parts 1 and 2 (2 class periods) Please refer to lessons 3.4 and 3.5: Safety, First Aid and Infant

More information

Pediatric Vaccine Products

Pediatric Vaccine Products Pediatric Vaccine Products Reference Guide As always, FFF goes Beyond Distribution in its commitment to lead with integrity and a patient-centered focus. We are constantly seeking innovative solutions

More information

Recommended Immunization Schedule for Adults Aged 19 Years or Older, United States, 2017

Recommended Immunization Schedule for Adults Aged 19 Years or Older, United States, 2017 Caring for Our Children: National Health and Safety Performance Standards H Recommended Immunization Schedule for Adults Aged 19 Years or Older, United States, 2017 In February 2017, the Recommended Immunization

More information

Advisory Committee on Immunization Practices VACCINE ACRONYMS

Advisory Committee on Immunization Practices VACCINE ACRONYMS May 1, 2015 Vaccine Acronyms Page 1 of 5 Advisy Committee on Immunization Practices VACCINE ACRONYMS Vaccines Included in the Immunization Schedules f Children, Adolescents, and Adults Following is a table

More information

Summary of Recommendations for Adult Immunization (Age 19 years and older) (Page 2 of 5)

Summary of Recommendations for Adult Immunization (Age 19 years and older) (Page 2 of 5) Summary of Recommendations for Adult Immunization (Age 19 years and older) (Page 1 of 5) Influenza Inactivated Influenza (IIV*) or ID (intradermally) *includes recombinant influenza (RIV) Live attenuated

More information

Summary of Recommendations for Adult Immunization (Age 19 years and older) PAGE 1 OF 5

Summary of Recommendations for Adult Immunization (Age 19 years and older) PAGE 1 OF 5 Summary of Recommendations for Adult Immunization (Age 19 years and older) PAGE 1 OF 5 Influenza Inactivated Influenza vaccine (IIV*) or ID (intradermally) * includes recombinant influenza vaccine (RIV3)

More information

Vaccines Indicated for Infants, Children, and Adolescents Based on Medical and Other Indications

Vaccines Indicated for Infants, Children, and Adolescents Based on Medical and Other Indications Vaccines Indicated for Infants, Children, and Adolescents Based on Medical and Other Indications Vaccine Prematurity 1 Altered Immunocompetence 2 (excluding human immunodefi ciency virus [HIV] infection)

More information

Advisory Committee on Immunization Practices VACCINE ACRONYMS

Advisory Committee on Immunization Practices VACCINE ACRONYMS Vaccine Acronyms Page 1 of 5 Advisy Committee on Immunization Practices VACCINE ACRONYMS Vaccines Included in the Immunization Schedules f Children, Adolescents, and Adults Following is a table of standardized

More information

Immunization Schedules on the Web... A-1. Childhood Immunization Schedule A-2. Adult Immunization Schedule A-6

Immunization Schedules on the Web... A-1. Childhood Immunization Schedule A-2. Adult Immunization Schedule A-6 ppendix PPENDIX Schedules and Recommendations Immunization Schedules on the Web... -1 Childhood Immunization Schedule 2012.... -2 dult Immunization Schedule 2012... -6 Recommended Minimum ges and Intervals....

More information

Vaccination Decision Making: What Providers Need to Know

Vaccination Decision Making: What Providers Need to Know Objectives Vaccination Decision Making: What Providers Need to Know Kelli Smith, RN, BSN Iowa Department of Public Health Immunization Program Catch-up Schedule: how to most efficiently bring persons up-to-date

More information

Recommended Childhood Immunization Schedu...ates, January - December 2000, NP Central

Recommended Childhood Immunization Schedu...ates, January - December 2000, NP Central Recommended Childhood Immunization Schedule United States, January - December 2000 Vaccines 1 are listed under routinely recommended ages. Solid-colored bars indicate range of recommended ages for immunization.

More information

7.0 Nunavut Childhood and Adult Immunization Schedules and Catch-up Aids

7.0 Nunavut Childhood and Adult Immunization Schedules and Catch-up Aids 7.0 Nunavut Childhood and Adult Immunization Schedules and Catch-up Aids Contents Introduction Nunavut Recommended Childhood Immunization Schedule Nunavut Routine Adult Immunization Schedule Nunavut Immunization

More information

Vaccine Label Examples

Vaccine Label Examples Vaccine Label Examples With the large amount of vaccine carried in most clinics, staff can easily become confused about vaccines within the storage unit. Labeling the area where vaccines are stored can

More information

Immunization Update Disclosures. Candice Robinson, MD, MPH Medical Officer Immunization Services Division 5/12/2017

Immunization Update Disclosures. Candice Robinson, MD, MPH Medical Officer Immunization Services Division 5/12/2017 Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Immunization Update 2017 Candice Robinson, MD, MPH Medical Officer Immunization Services Division Western

More information

Vaccines, Not Just for Babies

Vaccines, Not Just for Babies Vaccines, Not Just for Babies Meg Fisher, MD Medical Director Disclosures I have no relevant financial relationships with the manufacturers of any commercial products or commercial services discussed in

More information

Childhood Immunization Status

Childhood Immunization Status emeasure Title emeasure Identifier (Measure Authoring Tool) Childhood Immunization Status 117 emeasure Version number 5.1.000 NQF Number 0038 GUID b2802b7a-3580-4be8-9458- 921aea62b78c Measurement Period

More information

Immunizations (Guideline Intervals Using The Rule of Six for Vaccines Birth to Six Years)

Immunizations (Guideline Intervals Using The Rule of Six for Vaccines Birth to Six Years) Immunizations (Guideline Intervals Using The Rule of Six for Vaccines Birth to Six Years) Guideline developed by Shelly Baldwin, MD, in collaboration with the ANGELS Team. Last reviewed by Shelly Baldwin,

More information

Immunization Update: New CDC Recommendations. Blaise L. Congeni M.D. 2012

Immunization Update: New CDC Recommendations. Blaise L. Congeni M.D. 2012 Immunization Update: New CDC Recommendations Blaise L. Congeni M.D. 2012 Polysaccharide Vaccines Vaccine Hib capsule polysaccharide PRP (polyribose ribitol phosphate) Not protective in infants

More information

Vaccinations for Adults

Vaccinations for Adults Case: Vaccinations for Adults Lisa Winston, MD University of California, San Francisco San Francisco General Hospital A 30-year old healthy woman comes for a routine visit. She is recently married and

More information

Appendix An Assessment Tool to Determine the Validity of Vaccine Doses

Appendix An Assessment Tool to Determine the Validity of Vaccine Doses Appendix 4.4 - An Assessment Tool to Determine the Validity of Vaccine Doses Note: Refer to the Canadian Immunization Guide and New Brunswick (NB) immunization program directives for recommendations for

More information

Whose Calling the Shots? - A 2019 Vaccine Update. Frank Bell Swedish Pediatric Infectious Disease Jan 2019

Whose Calling the Shots? - A 2019 Vaccine Update. Frank Bell Swedish Pediatric Infectious Disease Jan 2019 Whose Calling the Shots? - A 2019 Vaccine Update Frank Bell Swedish Pediatric Infectious Disease Jan 2019 2019 Vaccine Update Vaccines Meningococcal serogroup B HPV Pertussis Influenza Children with uncertain

More information

Immunizations are among the most cost effective and widely used public health interventions.

Immunizations are among the most cost effective and widely used public health interventions. Focused Issue of This Month Recommended by the Korean Pediatric Society, 2008 Hoan Jong Lee, MD Department of Pediatrics, Seoul National University College of Medicine E mail : hoanlee@snu.ac.kr J Korean

More information

All Kindergarteners and 4-6 year old transfer students. 4 doses DTP or DTaP 1 dose must be at or after 4 years of age. None

All Kindergarteners and 4-6 year old transfer students. 4 doses DTP or DTaP 1 dose must be at or after 4 years of age. None Parents Vaccines Required for School Entry in Michigan Whenever children are brought into group settings, there is a chance for diseases to spread. Children must follow state vaccine laws in order to attend

More information

Immunization Recommendations for College Students

Immunization Recommendations for College Students May 2017 ACHA Guidelines Immunization Recommendations for College Students Immunizations offer safe and effective protection from vaccine-preventable diseases and outbreaks. The United States is experiencing

More information

UPDATE ON IMMUNIZATION GUIDELINES AND PRACTICES

UPDATE ON IMMUNIZATION GUIDELINES AND PRACTICES DISCLOSURES UPDATE ON IMMUNIZATION GUIDELINES AND PRACTICES Nothing to disclose Kylie Mueller, Pharm.D., BCPS Clinical Specialist, Infectious Diseases Spartanburg Regional Medical Center LEARNING OBJECTIVES

More information

MOLINA HEALTHCARE OF TEXAS

MOLINA HEALTHCARE OF TEXAS MOLINA HEALTHCARE OF TEXAS Preventive Care Guidelines: Ages 21 and Older GUIDELINE Molina Healthcare of Texas has adopted Preventive Care Guidelines: Ages 21 and Older. The guideline was reviewed and adopted

More information

Immunization Update 2016

Immunization Update 2016 Immunization Update 2016 Candice L. Robinson Medical Officer Immunization Services Division New Hampshire Immunization Conference Manchester, NH March 23, 2016 Disclosures Candice Robinson is a federal

More information

REACHING OUR GOALS: CHILDHOOD & ADOLESCENT IMMUNIZATION Illinois Chapter, American Academy of Pediatrics

REACHING OUR GOALS: CHILDHOOD & ADOLESCENT IMMUNIZATION Illinois Chapter, American Academy of Pediatrics REACHING OUR GOALS: CHILDHOOD & ADOLESCENT IMMUNIZATION 2017 Illinois Chapter, American Academy of Pediatrics Learning Objectives Provide the updates from 2017 Advisory Committee on Immunizations Practices

More information

ARKANSAS HEALTHY CHILDREN HANDBOOK

ARKANSAS HEALTHY CHILDREN HANDBOOK 6th Edition 2013 Chapter 4 Children s Health Histories, Physical Exams and Immunizations Chapter Content Immunization Records and Health Records and History Immunizations for Staff Guide for Measles Immunization

More information

Andrew Kroger, MD, MPH National Center for Immunization and Respiratory Diseases MCH & Immunization Conference Anchorage, AK September 28, 2010

Andrew Kroger, MD, MPH National Center for Immunization and Respiratory Diseases MCH & Immunization Conference Anchorage, AK September 28, 2010 2010 Immunization Update Andrew Kroger, MD, MPH National Center for Immunization and Respiratory Diseases MCH & Immunization Conference Anchorage, AK September 28, 2010 Disclosures No financial conflict

More information

Vaccine Label Examples

Vaccine Label Examples Vaccine Label Examples With the large amount of vaccine carried in most clinics, staff can easily become confused about vaccines within the storage unit. Labeling the area where vaccines are stored can

More information

Preventive care guidelines for children and adults.

Preventive care guidelines for children and adults. Preventive care guidelines for children and adults. Keeping a focus on regular preventive care can help you and your family stay healthy. Preventive care can help you avoid potentially serious health conditions

More information

What are the new active vaccine recommendations in the Canadian Immunization Guide?

What are the new active vaccine recommendations in the Canadian Immunization Guide? 154 CCDR 17 April 2014 Volume 40-8 https://doi.org/10.14745/ccdr.v40i08a03 1 What are the new active vaccine recommendations in the Canadian Immunization Guide? Warshawsky B 1 and Gemmill I 2 on behalf

More information

MMWR. 2009;58(RR02):1-25.

MMWR. 2009;58(RR02):1-25. Immunizations 2009 Chris Feddock, MD, MS, FAAP, FACP Objectives Outline the new ACIP vaccine recommendations Identify the new combination vaccines which are now available Recognize i the current vaccine

More information

Objectives. Adult Immunization Update. Questions. Immunology. Questions. Immune System

Objectives. Adult Immunization Update. Questions. Immunology. Questions. Immune System Objectives Adult Immunization Update Describe how vaccines teach the body to fight infections. List vaccines available for adults and the indications. Describe the recent updates for specific vaccines

More information

Birth 6 wk 10 wk 14 wk 18 wk 6 mo 9 mo 12 mo 15 mo 18 mo mo 2-3 Yr 4-6 Yr 7-10Yr Yr 13-18Yr

Birth 6 wk 10 wk 14 wk 18 wk 6 mo 9 mo 12 mo 15 mo 18 mo mo 2-3 Yr 4-6 Yr 7-10Yr Yr 13-18Yr Vaccine BCG Age Birth 6 wk 10 wk 14 wk 18 wk 6 mo 9 mo 12 mo 15 mo 18 mo 19-23 mo 2-3 Yr 4-6 Yr 7-10Yr 11-12 Yr 13-18Yr BCG Hep B Hep B1 Hep B2 Hep B3 Polio OPV 0 IPV1 IPV2 IPV3 OPV1 OPV2 IPV B1 OPV3 DTP

More information

Immunization Protocol with Procedures and Standing Orders for Nurses

Immunization Protocol with Procedures and Standing Orders for Nurses New Mexico Department of Health Immunization Protocol with Procedures and Standing Orders for Nurses Updated September 1, 2016 Minor Revision October 7, 2016 HPV Revision December 27, 2016 Immunization

More information

Revisions to Communicable Disease Control Manual: Chapter 2 Immunization Program

Revisions to Communicable Disease Control Manual: Chapter 2 Immunization Program January 5, 2010 ATTN: Medical Health Officers and Branch Offices Public Health Nursing Administrators and Assistant Administrators Holders of Communicable Disease Control Manuals Re: Revisions to Communicable

More information

ACIP Meeting Update, New Recommendations and Pending Influenza Season

ACIP Meeting Update, New Recommendations and Pending Influenza Season ACIP Meeting Update, New Recommendations and Pending Influenza Season February 17 th 2011 www.immunizetexas.com ACIP Upcoming Agenda and New Recommendations ACIP (February 23-24 th 2011) Topics for meeting

More information

Adult Vaccine Products

Adult Vaccine Products Adult Vaccine Products Reference Guide As always, FFF goes Beyond Distribution in its commitment to lead with integrity and a patient-centered focus. We are constantly seeking innovative solutions to reinforce

More information

Cigna Drug and Biologic Coverage Policy

Cigna Drug and Biologic Coverage Policy Cigna Drug and Biologic Coverage Policy Subject Routine Immunizations Table of Contents Coverage Policy... 1 General Background... 2 Coding/Billing Information... 3 References... 7 Effective Date... 4/15/2018

More information

Child Health and Disability Prevention (CHDP) Program Code Conversion

Child Health and Disability Prevention (CHDP) Program Code Conversion Child Health and Disability Prevention (CHDP) Program Code Conversion Health s All s are effective for dates of service on or after July 1, 2017. (Select s for laboratory-only providers with effective

More information

Immunization Update 2015

Immunization Update 2015 Immunization Update 2015 JoEllen Wolicki BSN, RN Immunization Services Division National Center for Immunization and Respiratory Diseases Tennessee Annual Spring Immunization Review April 2015 National

More information

Decision to amend access criteria for some vaccines

Decision to amend access criteria for some vaccines 3 July 2015 Decision to amend access criteria for some vaccines PHARMAC is pleased to announce the following changes to the funding access criteria for a number of vaccines. The changes in criteria follow

More information

07/20/17, 05/17/18 CATEGORY: Vaccines/Biologics. Proprietary Information of Excellus Health Plan, Inc.

07/20/17, 05/17/18 CATEGORY: Vaccines/Biologics. Proprietary Information of Excellus Health Plan, Inc. MEDICAL POLICY SUBJECT: IMMUNIZATIONS PAGE: 1 OF: 9 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product (including an Essential

More information

REACHING OUR GOALS: CHILDHOOD & ADOLESCENT IMMUNIZATION Illinois Chapter, American Academy of Pediatrics

REACHING OUR GOALS: CHILDHOOD & ADOLESCENT IMMUNIZATION Illinois Chapter, American Academy of Pediatrics REACHING OUR GOALS: CHILDHOOD & ADOLESCENT IMMUNIZATION 2017 Illinois Chapter, American Academy of Pediatrics Learning Objectives Provide the updates from 2017 Advisory Committee on Immunizations Practices

More information

Enrollment Packet Checklist. Non-Prescription Topical Medication Authorization Form. Forms/Instructions Given to Parents Checklist

Enrollment Packet Checklist. Non-Prescription Topical Medication Authorization Form. Forms/Instructions Given to Parents Checklist Wee Love Day Care & Learning Center 31700 Couchez St. St. Clair Shores MI 48082 p: 586.296.7102 f: 586.296.7103 WeeLoveDaycare.com Child s Name: Start Date: Enrollment Packet Checklist Enrollment Contract

More information

An Update on Pediatric Vaccines

An Update on Pediatric Vaccines Faculty Disclosure An Update on Pediatric Vaccines I have not had any relevant financial relationships with resulting commercial interests or conflicts of interest in the past 12 months. Rhya Strifling,

More information

Guidelines for Vaccinating Pregnant Women

Guidelines for Vaccinating Pregnant Women Guidelines for Vaccinating Pregnant Women March 2012 Guidelines for Vaccinating Pregnant Women Abstracted from recommendations of the Advisory Committee on Immunization Practices (ACIP) MARCH 2012 Risk

More information

immunisation in New Zealand

immunisation in New Zealand This appendix details the history of. Section A1.1 is a brief summary of when each vaccine was introduced to the National Immunisation Schedule (the Schedule). This summary includes vaccines which were

More information

A Review of the Pediatric Immunization Schedule

A Review of the Pediatric Immunization Schedule A Review of the Pediatric Immunization Schedule Michaela Christian PGY-1 Pharmacy Practice Resident Mercy Hospital, A Campus of Plantation General Hospital Michaela.Christian@Hcahealthcare.com Objectives

More information

These slides are the property of the presenter. Do not duplicate without express written consent.

These slides are the property of the presenter. Do not duplicate without express written consent. Cancer Survivorship Protecting Against Vaccine Preventable Diseases Heidi Loynes BSN, RN Immunization Nurse Educator Michigan Department of health and Human Services (MDHHS) loynesh@michigan.gov Are Vaccine-Preventable

More information

CPT 2016 Code Changes

CPT 2016 Code Changes CPT 2016 Code Changes Code Changes - Medicine New CPT 2016 New Codes Code Description 69209 Removal impacted cerumen using irrigation/lavage, unilateral 90620 Meningococcal recombinant protein and outer

More information

APEC Guidelines Immunizations

APEC Guidelines Immunizations Pregnancy provides an excellent opportunity to enhance a woman s protection against disease and to provide protection to the neonate during the first 3 to 6 months of life. Women of childbearing age should

More information

Guidelines for Vaccinating Pregnant Women

Guidelines for Vaccinating Pregnant Women Guidelines for Vaccinating Pregnant Women April 2013 Guidelines for Vaccinating Pregnant Women Abstracted from recommendations of the Advisory Committee on Immunization Practices (ACIP) April 2013 Risk

More information

Vaccines for infants- What has happened in the last year?

Vaccines for infants- What has happened in the last year? Vaccines for infants- What has happened in the last year? MARK H. SAWYER UCSD SCHOOL OF MEDICINE RADY CHILDREN S HOSPITAL SAN DIEGO Lots has happened and it can be a little confusing Infants used to require

More information

Immunizations June 5, Brenda Ormesher, MD Infectious Disease Peacehealth Medical Group Springfield, OR

Immunizations June 5, Brenda Ormesher, MD Infectious Disease Peacehealth Medical Group Springfield, OR Immunizations June 5, 2015 Brenda Ormesher, MD Infectious Disease Peacehealth Medical Group Springfield, OR Disclosures None Goals Understand basic public health impact of immunization Recognize types

More information

Appendice History of Vaccine Use in New Brunswick- Chronology of vaccine use in New Brunswick Public Health programs*

Appendice History of Vaccine Use in New Brunswick- Chronology of vaccine use in New Brunswick Public Health programs* Appendice 4.3 - History of Vaccine Use in New Brunswick- 4.3.1 - History of Vaccine Use in New Brunswick - chronological listing Chronology of vaccine use in New Brunswick Public Health programs* * Please

More information

Recommended immunization schedule for children and adolescents: Immunization Guideline (8th edition) released by the Korean Pediatric Society in 2015

Recommended immunization schedule for children and adolescents: Immunization Guideline (8th edition) released by the Korean Pediatric Society in 2015 Review article Korean J Pediatr 2016;59(12):461-465 pissn 1738-1061 eissn 2092-7258 Korean J Pediatr 2016;59(12):461-465 Korean J Pediatr Recommended immunization schedule for children and adolescents:

More information

Benefit Interpretation

Benefit Interpretation Benefit Interpretation Subject: Part B vs. Part D Vaccines Issue Number: BI-039 Applies to: Medicare Advantage Effective Date: May 1, 2017 Attachments: Part B Vaccines Diagnosis Code Limits Table of Contents

More information

CHAPTER 3 HEALTHCARE ISSUES IN THE CHILD HEALTHCARE TRENDS

CHAPTER 3 HEALTHCARE ISSUES IN THE CHILD HEALTHCARE TRENDS CHAPTER 3 HEALTHCARE ISSUES IN THE CHILD HEALTHCARE TRENDS Causes of infant mortality have changed from primarily infectious and nutritional to noninfectious causes such as congenital anomalies and perinatal

More information

Utah Immunization Guidebook

Utah Immunization Guidebook Utah Immunization Guidebook 2017 2018 For Schools, Early Childhood Programs and Healthcare Providers UTAH IMMUNIZATION GUIDEBOOK INTRODUCTION The Utah Immunization Program and the Utah State Board of Education

More information

Objectives. Immunity. Childhood Immunization Risk of Non-Vaccinated Children 12/22/2015

Objectives. Immunity. Childhood Immunization Risk of Non-Vaccinated Children 12/22/2015 Childhood Immunization Risk of Non-Vaccinated Children Bertha P. Rojas, Pharm.D. PGY-1 Pharmacy Resident South Miami Hospital Objectives Understand the definition of herd immunity Identify vaccine-preventable

More information

Update on Vaccine Recommendations. Objectives. Childhood Immunization Schedule At the Turn of the Century. New Horizons in Pediatrics April 30, 2017

Update on Vaccine Recommendations. Objectives. Childhood Immunization Schedule At the Turn of the Century. New Horizons in Pediatrics April 30, 2017 Centers for for Disease Disease Control Control and and Prevention Prevention National Center for Immunization and Respiratory Diseases Update on Vaccine Recommendations New Horizons in Pediatrics April

More information

Adult Vaccine Update. NB Internal Medicine Update, April 22 nd, 2016 Dan Smyth, MD, FRCPC, DTMH

Adult Vaccine Update. NB Internal Medicine Update, April 22 nd, 2016 Dan Smyth, MD, FRCPC, DTMH Adult Vaccine Update NB Internal Medicine Update, April 22 nd, 2016 Dan Smyth, MD, FRCPC, DTMH Summary points: Canadian adults > 18 should be regularly assessed to ensure recommended vaccinations are up

More information

Coverage of Vaccines Medicaid and Child Health Plus Members

Coverage of Vaccines Medicaid and Child Health Plus Members Coverage of Vaccines Medicaid and Child Health Plus Members For children between the ages 0-18, routine recommended vaccinations are covered through Vaccines for Children program [VFC]. Fidelis Care will

More information

Platforms. Adolescent Immunization Update and the 16 Year Old Platform. Advisory Committee on Immunization Practices (ACIP)

Platforms. Adolescent Immunization Update and the 16 Year Old Platform. Advisory Committee on Immunization Practices (ACIP) Adolescent Immunization Update and the 16 Year Old Platform William Atkinson, MD, MPH Associate Director for Immunization Education Immunization Action Coalition Advisory Committee on Immunization Practices

More information

American Osteopathic College of Occupational and Preventive Medicine 2012 Mid-Year Educational Conference St. Petersburg, Florida

American Osteopathic College of Occupational and Preventive Medicine 2012 Mid-Year Educational Conference St. Petersburg, Florida Vaccine policy in the US Disease Prevention and Control: Vaccination Recommendations and Travel Medicine Update Lisa A. Klatka, DO, MS Medina County Health Department Medina, OH Manufacturers publish product

More information

Early and Periodic Screening, Diagnosis and Treatment. Provider Orientation Packet

Early and Periodic Screening, Diagnosis and Treatment. Provider Orientation Packet Early and Periodic Screening, Diagnosis and Treatment Provider Orientation Packet EPSDT Provider Orientation Packet Table of Contents Frequently Asked Questions and EPSDT Department Responsibilities...

More information

HIT ME WITH YOUR BEST SHOT: UPDATE ON IMMUNIZATIONS. Karen Hoang, PharmD Clinical Pharmacy Specialist, MTM Services UPMC Health Plan

HIT ME WITH YOUR BEST SHOT: UPDATE ON IMMUNIZATIONS. Karen Hoang, PharmD Clinical Pharmacy Specialist, MTM Services UPMC Health Plan HIT ME WITH YOUR BEST SHOT: UPDATE ON IMMUNIZATIONS Karen Hoang, PharmD Clinical Pharmacy Specialist, MTM Services UPMC Health Plan DISCLOSURES No financial or other conflicts to disclose LEARNING OBJECTIVES

More information

I certify that the information provided on this form is correct and verifiable. Month Day Year

I certify that the information provided on this form is correct and verifiable. Month Day Year Certificate of Immunization Status (CIS) DOH 48-0 January 05 Please print. See back for instructions on how to fill out this form or get it printed from the Immunization Information System. Child s Last

More information

C o l o r a d o I m m u n i z a t i o n M a n u a l S E C T I O N 8 Vaccines

C o l o r a d o I m m u n i z a t i o n M a n u a l S E C T I O N 8 Vaccines S E C T I O N 8 Vaccines 8. Vaccines I S S U E D : 9 / 1 / 9 8 R E V I S E D : 5 / 1 / 1 1 S E C T I O N - P A G E : 8-1 S U B J E C T : C O N T E N T S CONTENTS S E C T I O N 8 Vaccines DTaP...............................................

More information

2015 ACIP Immunization Schedules & Recommendations and MDPH Updates

2015 ACIP Immunization Schedules & Recommendations and MDPH Updates Massachusetts Department of Public Health Division of Epidemiology and Immunization 2015 ACIP Immunization Schedules & Recommendations and MDPH Updates Susan M. Lett, MD, MPH Medical Director, Immunization

More information

The National Immunisation Schedule Update and Current issues. Dr Brenda Corcoran National Immunisation Office.

The National Immunisation Schedule Update and Current issues. Dr Brenda Corcoran National Immunisation Office. The National Immunisation Schedule Update and Current issues Dr Brenda Corcoran National Immunisation Office : Dates vaccines introduced into the Irish immunisation schedule Vaccine 1937-1999 Date introduced

More information

Preventive care services for commercial members

Preventive care services for commercial members Preventive care services for commercial members This schedule is a reference tool for planning your preventive care, and lists items/services covered under the Patient Protection and Affordable Care Act

More information

Standard For Recommended Immunization Schedules

Standard For Recommended Immunization Schedules Standard For Recommended Immunization Schedules Section 3: Immunization General Principles Standard #: 03.110 Created by: Province-wide Immunization Program Standards and Quality Approved by: Dr. Predy,

More information

2/16/2015 IMMUNIZATION UPDATE Kelly Ridgway, RPh February 21, Today s Overview NEW RECOMMENDATIONS

2/16/2015 IMMUNIZATION UPDATE Kelly Ridgway, RPh February 21, Today s Overview NEW RECOMMENDATIONS IMMUNIZATION UPDATE 2015 Kelly Ridgway, RPh February 21, 2015 Today s Overview 1 2 3 4 5 6 Pneumococcal Vaccine Recommendations Meningococcal Vaccine Recommendations HPV Vaccine Recommendations Patient

More information